Multiple Acquired Mutations Captured by Liquid Biopsy in the EGFR Addicted Metastatic Colorectal Cancer

Guerrera, Luigi Pio; Napolitano, Stefania; Falco, Vincenzo De; Giunta, Emilio Francesco; Vitiello, Pietro Paolo; Gravina, Antonietta Gerarda; Suarato, Gabriella; Perrone, Alessandra; Napolitano, Rossella; Martinelli, Erika; Troiani, Teresa

doi:10.1016/j.clcc.2021.07.005

Cited by 2 publications

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On-target resistance mutations were also identified in the EGFR gene affecting noncanonical positions p.(Gly465Arg), EGFR p.(Ser464Leu), EGFR p.(Gly465Glu), EGFR p.(Val441Asp), EGFR p.(Val441Gly), EGFR p.(Lys489Glu), EGFR p.(Ile491Arg), EGFR p.(Ser464Lys), EGFR p.(Ser464Phe), EGFR p.(Ile491Lys). All mutations were identified at very low allelic frequency (ranging from 0.36% to 4.70%) [ 42 ].…”

Section: Early Detection Of Complex Drug-resistance Mechanismsmentioning

confidence: 99%

Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test

Vasseur

Sahli

Bayle

et al. 2022

Cells

View full text Add to dashboard Cite

FDA-approved next-generation sequencing assays based on cell-free DNA offers new opportunities in a molecular-tumor-board context thanks to the noninvasiveness of liquid biopsy, the diversity of analyzed parameters and the short turnaround time. It gives the opportunity to study the heterogeneity of the tumor, to elucidate complex resistance mechanisms and to adapt treatment strategies. However, lowering the limit of detection and increasing the panels’ size raise new questions in terms of detection of incidental germline alterations, occult malignancies and clonal hematopoiesis of indeterminate potential mutations. In this review, after a technological discussion and description of the common problematics encountered, we establish recommendations in properly using these FDA-approved tests in a molecular-tumor-board context.

show abstract

Section: Early Detection Of Complex Drug-resistance Mechanismsmentioning

confidence: 99%

Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test

Vasseur

Sahli

Bayle

et al. 2022

Cells

View full text Add to dashboard Cite

show abstract

Dynamics of RAS Mutations in Liquid Biopsies in Metastatic Colorectal Cancer Patients—Case Series and Literature Review

Popescu,

Croitoru,

Croitoru-Cazacu

et al. 2024

JPM

View full text Add to dashboard Cite

Liquid biopsies can accurately identify molecular alterations in patients with colorectal cancer with high concordance with tissue analysis and shorter turnaround times. Circulating tumor (ct) DNA analysis can be used for diagnosing and monitoring tumor evolution in patients with metastatic colorectal cancer who are treated with EGFR inhibitors. In this article, we reported three clinical cases to illustrate the relevance of RAS mutations identified in ctDNA samples of patients with wild-type metastatic colorectal cancer who received an EGFR inhibitor plus chemotherapy as first-line treatment. The identification of RAS mutations in these patients is one of the most frequently identified mechanisms of acquired resistance. However, detecting a KRAS mutation via liquid biopsy can be caused by inter-tumor heterogeneity or it can be a false positive due to clonal hematopoiesis. More research is needed to determine whether ctDNA monitoring may help guide therapy options in metastatic colorectal cancer patients. We performed a literature review to assess the technologies that are used for analysis of RAS mutations on ctDNA, the degree of agreement between tissue and plasma and the importance of tissue/plasma discordant cases.

show abstract

Multiple Acquired Mutations Captured by Liquid Biopsy in the EGFR Addicted Metastatic Colorectal Cancer

Cited by 2 publications

References 15 publications

Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test

Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test

Dynamics of RAS Mutations in Liquid Biopsies in Metastatic Colorectal Cancer Patients—Case Series and Literature Review

Contact Info

Product

Resources

About